S&P 500
(0.12%) 5 303.27 points

Dow Jones
(0.34%) 40 004 points

Nasdaq
(-0.07%) 16 686 points

Oil
(-0.05%) $80.02

Gas
(1.56%) $2.67

Gold
(1.01%) $2 441.90

Silver
(4.15%) $32.56

Platinum
(1.34%) $1 104.60

USD/EUR
(-0.06%) $0.919

USD/NOK
(-0.07%) $10.67

USD/GBP
(0.00%) $0.787

USD/RUB
(-0.03%) $90.94

Realtime updates for Glenmark Life Sciences [GLS.NS]

Exchange: NSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic

Last Updated18 May 2024 @ 03:00

25% discount on Stockinvest.us - Use code: Podcast

-0.65% INR 822.55

Live Chart Being Loaded With Signals

Commentary (18 May 2024 @ 03:00):

Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India...

Stats
Today's Volume	8 392.00
Average Volume	128 746
Market Cap	100.78B
EPS	INR9.69 ( 2023-10-20 )
Last Dividend	INR21.00 ( 2023-03-24 )
Next Dividend	INR0 ( N/A )
P/E	21.44
ATR14	INR1.066 (0.13%)

Volume Correlation

Long: 0.00 (neutral)

Short: -0.42 (neutral)

Signal:(49.56) Neutral

Glenmark Life Sciences Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Glenmark Life Sciences Correlation - Currency/Commodity

0.03
( neutral )

0.14
( neutral )

0.17
( neutral )

0.66
( moderate )

-0.55
( weak negative )

-0.46
( neutral )

Glenmark Life Sciences Financials

Annual	2023
Revenue:	INR22.83B
Gross Profit:	INR12.81B (56.11 %)
EPS:	INR38.43

FY	2023
Revenue:	INR22.83B
Gross Profit:	INR12.81B (56.11 %)
EPS:	INR38.43

FY	2022
Revenue:	INR21.61B
Gross Profit:	INR11.47B (53.08 %)
EPS:	INR38.11

FY	2022
Revenue:	INR21.23B
Gross Profit:	INR10.80B (50.88 %)
EPS:	INR35.63

Financial Reports:

No articles found.

Glenmark Life Sciences Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR10.50 (N/A)	INR0 (N/A)	INR21.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Glenmark Life Sciences Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.63 - Stable (12.57%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR10.50	2021-11-22
Last Dividend	INR21.00	2023-03-24
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	INR42.00	--
Avg. Dividend % Per Year	1.99%	--
Score	4.06	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.63
Div. Directional Score	9.12	--

Next Divdend (Est)
(2024-12-18)

INR0 Estimate 0.00 %

Dividend Stability

0.07 Very Bad

Dividend Score

4.06

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2021	INR10.50	1.40%
2022	INR10.50	1.68%
2023	INR21.00	5.03%
2024	INR0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
SATINDLTD.NS	Dividend Knight	2023-07-11	Semi-Annually	2	0.10%
MAGADSUGAR.NS	Dividend Knight	2023-07-13	Annually	7	1.78%
GICRE.NS	Dividend Junior	2023-09-07	Sporadic	7	1.34%
ARVSMART.NS	Dividend Junior	2023-07-21	Sporadic	6	0.13%
TOUCHWOOD.NS	Dividend Junior	2023-09-22	Annually	6	0.15%
PFC.NS	Dividend King	2023-06-16	Quarterly	18	7.12%
JAGSNPHARM.NS	Dividend Junior	2023-08-21	Annually	22	1.32%
CYIENT.NS	Dividend Knight	2023-06-12	Annually	18	1.81%
SJVN.NS	Dividend Knight	2023-09-21	Semi-Annually	15	4.18%
MBAPL.NS	Dividend Junior	2023-09-18	Annually	8	0.44%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.206	1.500	5.88	8.81	[0 - 0.5]
returnOnAssetsTTM	0.165	1.200	4.49	5.39	[0 - 0.3]
returnOnEquityTTM	0.204	1.500	8.85	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.37	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	2.64	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	0.687	1.500	7.29	10.00	[0.2 - 2]
debtRatioTTM	0.00602	-1.500	9.90	-10.00	[0 - 0.6]
interestCoverageTTM	408.14	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	6.33	2.00	7.89	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.33	2.00	6.83	10.00	[0 - 20]
debtEquityRatioTTM	0.00735	-1.500	9.97	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.561	1.000	3.98	3.98	[0.2 - 0.8]
operatingProfitMarginTTM	0.276	1.000	6.47	6.47	[0.1 - 0.6]
cashFlowToDebtRatioTTM	4.54	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.801	0.800	7.99	6.39	[0.5 - 2]
Total Score				12.61

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	21.47	1.000	7.93	0	[1 - 100]
returnOnEquityTTM	0.204	2.50	9.26	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.33	2.00	7.89	10.00	[0 - 30]
dividendYielPercentageTTM	2.74	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.33	2.00	7.89	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	2.01	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0341	1.000	-1.648	0	[0.1 - 0.5]
Total Score				5.63

Glenmark Life Sciences Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Glenmark Life Sciences

Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system diseases; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for diabetes; and Etoricoxib and Lornoxicam for pain management. It also provides Atovaquone, Voriconazole, Mirabegron, Desloratadine, Esomeprazole Magnesium, Adapalene, and Fluconazole gastro-intestinal disorders, anti-infective, respiratory, anti-emetic, and other therapeutic areas. In addition, the company offers contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Glenmark Pharmaceuticals Limited.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.